Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 586 AL 600

Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways

Sinha JK, Trisal A, Ghosh S, Gupta S, Singh KK, Han SS, Mahapatra M, Abomughaid MM, Abomughayedh AM, Almutary AG, Iqbal D, Bhaskar R, Mishra PC, Jha SK, Jha NK, Singh AK.

Ageing Res Rev. 2024 Apr;96:102211. doi: 10.1016/j.arr.2024.102211. Epub 2024 Feb 1.

Could protein phosphatase 2A and glycogen synthase kinase-3 beta be targeted by natural compounds to ameliorate Alzheimer's pathologies?

Manoharan SD, Abdul Hamid H, Md Hashim NF, Cheema MS, Chiroma SM, Mustapha M, Mehat MZ.

Brain Res. 2024 Apr 15;1829:148793. doi: 10.1016/j.brainres.2024.148793. Epub 2024 Feb 1.

Therapeutic potential of the medicinal mushroom Ganoderma lucidum against Alzheimer's disease

Chen XJ, Deng Z, Zhang LL, Pan Y, Fu J, Zou L, Bai Z, Xiao X, Sheng F.

Biomed Pharmacother. 2024 Mar;172:116222. doi: 10.1016/j.biopha.2024.116222. Epub 2024 Feb 3.

The effects of probiotic supplements on oxidative stress and inflammation in subjects with mild and moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled study

Akhgarjand C, Vahabi Z, Shab-Bidar S, Anoushirvani A, Djafarian K.

Inflammopharmacology. 2024 Apr;32(2):1413-1420. doi: 10.1007/s10787-023-01427-2. Epub 2024 Feb 6.

How donanemab data address the coverage with evidence development questions

Klein EG, Schroeder K, Wessels AM, Phipps A, Japha M, Schilling T, Zimmer JA.

Alzheimers Dement. 2024 Apr;20(4):3127-3140. doi: 10.1002/alz.13700. Epub 2024 Feb 7.

Memantine's double duty? Investigating its impact on epilepsy control in Alzheimer's disease

Rayala H, Kapur J, El-Haija HA, Parikh P, Zawar I.

Epileptic Disord. 2024 Apr;26(2):261-263. doi: 10.1002/epd2.20202. Epub 2024 Feb 9.

Artificial intelligence for drug discovery and development in Alzheimer's disease

Qiu Y, Cheng F.

Curr Opin Struct Biol. 2024 Apr;85:102776. doi: 10.1016/j.sbi.2024.102776. Epub 2024 Feb 8.

Acid sphingomyelinase as a pathological and therapeutic target in neurological disorders: focus on Alzheimer's disease

Choi BJ, Park MH, Jin HK, Bae JS.

Exp Mol Med. 2024 Feb;56(2):301-310. doi: 10.1038/s12276-024-01176-4. Epub 2024 Feb 9.

Extra-Virgin Olive Oil in Alzheimer's Disease: A Comprehensive Review of Cellular, Animal, and Clinical Studies

Alkhalifa AE, Al-Ghraiybah NF, Kaddoumi A.

Int J Mol Sci. 2024 Feb 5;25(3):1914. doi: 10.3390/ijms25031914.

Dual-target inhibitors of cholinesterase and GSK-3β to modulate Alzheimer's disease

He J, Tam KY.

Drug Discov Today. 2024 Apr;29(4):103914. doi: 10.1016/j.drudis.2024.103914. Epub 2024 Feb 8.

Developing a PRogram to Educate and Sensitize Caregivers to Reduce the Inappropriate Prescription Burden in the Elderly with Alzheimer's Disease (D-PRESCRIBE-AD): Trial protocol and rationale of an open-label pragmatic, prospective randomized controlled trial

Singh S, Cocoros NM, Li X, Mazor KM, Antonelli MT, Parlett L, Paullin M, Harkins TP, Zhou Y, Rochon PA, Platt R, Dashevsky I, Massino C, Saphirak C, Crawford SL, Gurwitz JH.

PLoS One. 2024 Feb 12;19(2):e0297562. doi: 10.1371/journal.pone.0297562. eCollection 2024.

The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?

You Y, Chen Z, Hu WW.

Pharmacol Ther. 2024 Mar;255:108606. doi: 10.1016/j.pharmthera.2024.108606. Epub 2024 Feb 10.

Targeting Abnormal Tau Phosphorylation for Alzheimer's Therapeutics

Singh A, Ansari VA, Mahmood T, Hasan SM, Wasim R, Maheshwari S, Akhtar J, Sheikh S, Vishwakarma VK.

Horm Metab Res. 2024 Jul;56(7):482-488. doi: 10.1055/a-2238-1384. Epub 2024 Feb 13.

Alzheimer's therapeutic development: shifting neurodegeneration to neuroregeneration

Sun MK, Alkon DL.

Trends Pharmacol Sci. 2024 Mar;45(3):197-209. doi: 10.1016/j.tips.2024.01.012. Epub 2024 Feb 14.

Berberine: A Multi-Target Natural PCSK9 Inhibitor with the Potential to Treat Diabetes, Alzheimer's, Cancer and Cardiovascular Disease

Coppinger C, Pomales B, Movahed MR, Marefat M, Hashemzadeh M.

Curr Rev Clin Exp Pharmacol. 2024;19(4):312-326. doi: 10.2174/0127724328250471231222094648.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias